Around the world healthcare stakeholders are working to improve real-world patient outcomes through treatment innovations, care provision and access to healthcare. For the information, technology and service solutions they need to drive new insights and approaches, they count on QuintilesIMS. With a global team of 50,000, we harness insights, commercial and scientific depth, and executional expertise to empower clients to achieve some of their most important goals: Improving clinical, scientific and commercial results. Realizing the full potential of innovations. And, ultimately, driving healthcare forward.
From FORTUNE Magazine, March 1, 2017 ©2017 Time Inc. Used under license. FORTUNE and Time Inc. are not affiliated with, and do not endorse products or services of, QuintilesIMS.
QuintilesIMS starts a new chapter as a publicly traded company (NYSE:Q). The company’s 50,000 professionals serve clients in 100+ markets—working to advance healthcare by seamlessly connecting clinical and commercial execution to real-world outcomes.
IMS and Quintiles announce intention to merge to create a global leader in healthcare intelligence.
IMS acquires Cegedim’s CRM business and strategic data assets—affirming its position as the first global enterprise focused on connecting solutions across information, technology and services to drive healthcare performance.
IMS goes public again following four years as a private company.
IMS completes a series of strategic acquisitions to strengthen technology services and solutions—including social media listening, multichannel marketing and performance management, as well as technology-enabled Real-World Insights solutions.
Quintiles acquires Outcome Sciences, positioning Quintiles as the industry powerhouse in late-phase and real-world research.
IMS expands specialty and anonymized patient-level data assets in the U.S. with the acquisition of SDI Health.
IMS is taken private by TPG Capital, CPP Investment Board and Leonard Green & Partners. Valued at close to $6 billion, the deal is the largest leveraged buyout transaction closed in the prior three years.
Quintiles becomes a private company led by founder and Chairman Dennis Gillings, CBE, PhD.
IMS extends consulting and advisory services by acquiring U.K.-based Cambridge Pharma Consultancy.
IMS becomes an independent, NYSE-listed public company.
Quintiles combines with Innovex Ltd., a UK-based contract pharmaceutical company specializing in sales and marketing services for pharmaceutical clients, creating the world’s largest full-service biopharmaceutical services company.
Quintiles establishes its Consulting practice with the acquisition of a globally recognized healthcare policy research and management consulting company.
Quintiles goes public, completing an initial public offering of Quintiles stock.
Quintiles Laboratories Ltd. opens in Atlanta, expanding from one small room offering safety testing to a global network with a full-service offering, before becoming Q2LabSolutions in a transaction with Quest Diagnostics.
D&B acquires IMS for nearly $1.7 billion to leverage the complementary strengths of IMS and sister division A.C. Nielsen.
Dennis Gillings and Gary Koch, professors at the University of North Carolina, co-found Quintiles with a team of part-time staff working in a trailer on the UNC campus where they provide statistical and data management consulting for pharmaceutical clients.
IMS launches MIDAS, which gives clients access to IMS databases from terminals in their offices.
IMS acquires Cambridge Computer, the creator of Drug Distribution Data (DDD), which becomes one of IMS's most significant product lines.
IMS publishes its first European syndicated research study: an audit of pharma sales in West Germany. Acquisitions in South Africa, Australia and New Zealand follow.
Bill Frohlich, an ad executive, and David Dubow, a visionary, form IMS as the first independent, objective source of information about the pharmaceutical industry.